Despite the strong profitability momentum in the operating segments, except for the expected moderation in Diagnostics, the management’s guidance is now for the lower end of the adjusted EPS guidance owing to the end to the central banks’ cheap money policy which is starting to negatively impact Healthineers’ P&L. We expect the company to deliver a strong Q4 and, in our view, the investor disappointment (shares down ~ -7%) is overdone.